218 related articles for article (PubMed ID: 3730943)
1. The contribution of alkylation to the activity of quinone antitumor agents.
Begleiter A
Can J Physiol Pharmacol; 1986 May; 64(5):581-5. PubMed ID: 3730943
[TBL] [Abstract][Full Text] [Related]
2. Activity of quinone alkylating agents in quinone-resistant cells.
Begleiter A; Leith MK
Cancer Res; 1990 May; 50(10):2872-6. PubMed ID: 1692249
[TBL] [Abstract][Full Text] [Related]
3. Studies on the mechanism of action of quinone antitumor agents.
Begleiter A
Biochem Pharmacol; 1985 Aug; 34(15):2629-36. PubMed ID: 4015705
[TBL] [Abstract][Full Text] [Related]
4. Quinone-induced DNA damage and its relationship to antitumor activity in L5178Y lymphoblasts.
Begleiter A; Blair GW
Cancer Res; 1984 Jan; 44(1):78-82. PubMed ID: 6537800
[TBL] [Abstract][Full Text] [Related]
5. Characterization of L5178Y murine lymphoblasts resistant to quinone antitumor agents.
Begleiter A; Leith MK; McClarty G; Beenken S; Goldenberg GJ; Wright JA
Cancer Res; 1988 Apr; 48(7):1727-35. PubMed ID: 3127038
[TBL] [Abstract][Full Text] [Related]
6. The role of drug transport in resistance to nitrogen mustard and other alkylating agents in L518Y lymphoblsts.
Goldenberg GJ
Cancer Res; 1975 Jul; 35(7):1687-92. PubMed ID: 1055634
[TBL] [Abstract][Full Text] [Related]
7. Cytocidal action of the quinone group and its relationship to antitumor activity.
Begleiter A
Cancer Res; 1983 Feb; 43(2):481-4. PubMed ID: 6848172
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms for the modulation of alkylating activity by the quinone group in quinone alkylating agents.
Begleiter A; Leith MK; Pan SS
Mol Pharmacol; 1991 Sep; 40(3):454-8. PubMed ID: 1896030
[TBL] [Abstract][Full Text] [Related]
9. Increased sensitivity of quinone resistant cells to mitomycin C.
Begleiter A; Robotham E; Lacey G; Leith MK
Cancer Lett; 1989 Jun; 45(3):173-6. PubMed ID: 2471583
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity study with bioreductive benzoquinone alkylating agents: effects on DT-diaphorase-mediated DNA crosslink and strand break formation in relation to mechanisms of cytotoxicity.
Fourie J; Guziec F; Guziec L; Monterrosa C; Fiterman DJ; Begleiter A
Cancer Chemother Pharmacol; 2004 Mar; 53(3):191-203. PubMed ID: 14614574
[TBL] [Abstract][Full Text] [Related]
11. Mono and bis(bioreductive) alkylating agents: synthesis and antitumor activities in a B16 melanoma model.
Witiak DT; Loper JT; Ananthan S; Almerico AM; Verhoef VL; Filppi JA
J Med Chem; 1989 Jul; 32(7):1636-42. PubMed ID: 2738896
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic mechanisms of anti-tumour quinones in parental and resistant lymphoblasts.
Halinska A; Belej T; O'Brien PJ
Br J Cancer Suppl; 1996 Jul; 27():S23-7. PubMed ID: 8763840
[TBL] [Abstract][Full Text] [Related]
13. Cellular pharmacology of quinone bioreductive alkylating agents.
Rockwell S; Sartorelli AC; Tomasz M; Kennedy KA
Cancer Metastasis Rev; 1993 Jun; 12(2):165-76. PubMed ID: 8375019
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of cytosolic glutathione S-transferases in drug-resistant L5178Y murine lymphoblasts: chemical selectivity and molecular mechanisms.
Stelmack GL; Goldenberg GJ
Cancer Res; 1993 Aug; 53(15):3530-5. PubMed ID: 8101761
[TBL] [Abstract][Full Text] [Related]
15. Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines.
Teicher BA; Cucchi CA; Lee JB; Flatow JL; Rosowsky A; Frei E
Cancer Res; 1986 Sep; 46(9):4379-83. PubMed ID: 3731096
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the DNA-DNA cross-linking activity of 3'-(3-cyano-4-morpholinyl)-3'-deaminoadriamycin.
Jesson MI; Johnston JB; Robotham E; Begleiter A
Cancer Res; 1989 Dec; 49(24 Pt 1):7031-6. PubMed ID: 2531036
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms of trenimon-induced cytotoxicity in resistant L5178Y/HBM10 cells.
Silva JM; O'Brien PJ
Int J Radiat Oncol Biol Phys; 1992; 22(4):639-42. PubMed ID: 1371987
[TBL] [Abstract][Full Text] [Related]
18. Investigation of resistance to DNA cross-linking agents in 9L cell lines with different sensitivities to chloroethylnitrosoureas.
Bodell WJ; Gerosa M; Aida T; Berger MS; Rosenblum ML
Cancer Res; 1985 Aug; 45(8):3460-4. PubMed ID: 3860285
[TBL] [Abstract][Full Text] [Related]
19. Preclinical studies and clinical correlation of the effect of alkylating dose.
Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY
Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059
[TBL] [Abstract][Full Text] [Related]
20. Cross-linking and sequence specific alkylation of DNA by aziridinyl quinones. 2. Structure requirements for sequence selectivity.
Hargreaves RH; Mayalarp SP; Butler J; McAdam SR; O'Hare CC; Hartley JA
J Med Chem; 1997 Jan; 40(3):357-61. PubMed ID: 9022802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
